Aug 2026· Zhonghua zhong liu za zhi [Chinese journal of oncology]· Vol 48 8, pp.
954-962
· 0 citations
Medicine
TL;DR
GLUT10 is highly expressed in breast cancer and mediates cisplatin resistance by regulating ROS levels, suggesting it may serve as a novel therapeutic target for reversing drug resistance in breast cancer.
In MCF-7 and MDA-MB-231 cells, TBX20 overexpression significantly enhanced cell proliferation, migration, invasion, and resistance to doxorubicin, while suppressing the expression of mitophagy-related proteins LC3-II/LC3-I, PINK1, and BNIP3.
Shuai Nie, Dejian Liu, Jun Hu et al.· PLoS ONE· 0 citations
Higher circ_0027446 expression was associated with larger tumor size, lymph node metastasis, advanced TNM stage, and shorter overall survival, and may contribute to tumor progression and immune escape-related changes, at least partly through the miR-6882-3p/HOXB9 axis.
Qing-Ye Zhao, Chen Qin, Jie Chai et al.· Journal of Molecular Histolo...· 0 citations
The study demonstrates that TFEB regulates the expression of the multidrug efflux transporter ATP-binding cassette subfamily G member 2 (ABCG2), a crucial factor in drug resistance mechanisms, and targets TNKS represents a potentially effective therapeutic approach to address cisplatin resistance and improve treatment outcomes in TNBC.
Shariqa Jan, Kaneez Fatima, S. Khan et al.· Molecular Biology Reports· 0 citations
PON2 appears to sustain chemoresistance by affecting important mechanisms related to ROS detoxification, glucose metabolism, and anti-apoptotic signaling by affecting important mechanisms related to ROS detoxification, glucose metabolism, and anti-apoptotic signaling.
Eleonora Gerini, V. Pompei, M. Cecati et al.· Molecular Biology Reports· 0 citations
It is demonstrated that NAC1 may be a critical factor in the development of chemoresistance, offering a potential novel target for the treatment of CRC.
Tong-Fa Ju, Huicheng Jin, Rongchao Ying et al.· 0 citations
